Douglas E. Giordano
Vice President
Pfizer Worldwide Business Development

Doug Giordano is currently a Vice President in Pfizer’s Worldwide Business Development Group responsible for leading the negotiations and execution of product licensing and M&A transactions.  Over the past two years Doug has led teams responsible for all Pfizer acquisitions and product licensing transactions including Pfizer’s acquisitions of Coley, CovX. Encysive and Serenex, and product collaborations announced with Adolor, Avant, and Medivation.

Before joining Pfizer’s Worldwide Business Development group in 2007, Doug was of member of Pfizer’s US leadership team responsible for US strategy and business development.  Doug has been a key contributor to a variety of Pfizer transactions and a variety of innovative US commercialization initiatives including the creation and launch of the Pfizer/Microsoft/IBM collaboration, Amicore and the launch of the Pfizer for Living ShareCard and Pfizer Helpful Answers programs.

Before his US pharmaceuticals operating role, Doug worked in a mergers and acquisitions role within Pfizer’s Medical Technology Group – playing a key role in Pfizer’s acquisitions, technology licensing and divestiture activity within medtech.

Doug holds a Bachelor’s Degree in Biomedical Engineering from Duke University and an M.B.A. degree from Cornell University’s Johnson School of Business.